Intensity of Lipid Lowering With Statins and Brachial Artery Vascular Endothelium Reactivity After Acute Coronary Syndromes (from the BRAVER Trial)

Dupuis, Jocelyn; Tardif, Jean‐Claude; Rouleau, Jean‐Lucien; Ricci, Joseph; Arnold, Malcolm; Lonn, Eva; Roux, René L.; Title, Lawrence M.; Amyot, R; Bonafede, Nickie; Woo, Anna; Cannon, Christopher P.

doi:10.1016/j.amjcard.2005.06.057

Cited by 34 publications

(24 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Few studies have examined changes in FMD after switching statins and a study of a small patient cohort found no difference in FMD between patients already on a regular statin who switched to an aggressive type, or continued with the regular statin 22) . Kitta et al reported more recently that persistently impaired FMD after 6 months of optimized therapy, including statins, is associated with a poor outcome in patients with CAD 23) .…”

Section: Discussionmentioning

confidence: 99%

Switching to Aggressive Statin Improves Vascular Endothelial Function in Patients with Stable Coronary Artery Disease

Hoshiga

Arishiro

Nakakoji

et al. 2010

J Atheroscler Thromb

View full text Add to dashboard Cite

Aim:The clinical relevance of the suggested pleiotropic effects of hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) is controversial. Aggressive statins effectively reduce lipid levels, but whether their other effects are more powerful than those of regular statins is unknown. Methods: We enrolled 32 patients (mean age, 65 y; male, 23) who had undergone coronary revascularization over 6 months previously and whose serum LDL cholesterol levels persisted at 100 mg/dL, regardless of pravastatin (10 mg/day). Before and 1 and 6 months after switching to atorvastatin (10 mg/day), we evaluated lipid profiles, including RLP-C (remnant-like particle cholesterol), high sensitive CRP (

show abstract

Section: Discussionmentioning

confidence: 99%

Switching to Aggressive Statin Improves Vascular Endothelial Function in Patients with Stable Coronary Artery Disease

Hoshiga

Arishiro

Nakakoji

et al. 2010

J Atheroscler Thromb

View full text Add to dashboard Cite

show abstract

“…The present results are consistent with those of a previous study demonstrating that coronary vasomotor function is increased by statin treatment. 21 In addition, β-blockers can induce coronary spasms by converting the effect of a sympathetic stimulus into a pure α-adrenergic vasoconstrictor response. 22 YANO H et al…”

Section: Discussionmentioning

confidence: 99%

Effects of Valsartan, an Angiotensin II Receptor Blocker, on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction Who Receive an Angiotensin-Converting Enzyme Inhibitor

Yano

Hibi

Nozawa

et al. 2012

Circ J

View full text Add to dashboard Cite

Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp atients with acute myocardial infarction (AMI) have a greatly increased risk of subsequent fatal and non-fatal cardiovascular events. Pharmacotherapy is widely accepted to be effective for secondary prevention, but a considerable number of patients still have cardiovascular events. Many randomized, placebo-controlled trials have demonstrated that inhibition of the renin-angiotensin-aldosterone system (RAS) by treatment with an angiotensin-converting enzyme inhibitor (ACEI) reduces the risk of death as well as of major non-fatal cardiovascular events after AMI, and prevents events related to ischemia and atherosclerosis, regardless of blood pressure. 1,2Angiotensin II receptor blockers (ARBs) are thought to act through angiotensin type 1 receptors without affecting the breakdown of bradykinin, thereby avoiding the undesirable side-effects of ACEIs. ARBs may offer thus an alternative approach to RAS inhibition. Recent trials have demonstrated that ARBs are as effective as ACEIs in improving survival and reducing cardiovascular morbidity in patients with congestive heart failure. 3-5 These findings suggest that combined treatment with an ACEI and ARB might more systematically inhibit RAS than ACEI monotherapy. The combined effects of these drugs might thus have higher anti-atherosclerotic efficacy. Whether a combination of these drugs has a favorable effect on coronary atherosclerosis in patients with AMI after successful coronary revascularization, however, remains to be The aim of the present study was to assess the effects of angiotensin II receptor blocker (ARB) on coronary plaque progression in patients with acute myocardial infarction (AMI) who received an angiotensin-converting enzyme inhibitor (ACEI).

show abstract

“…Some studies have replicated this finding, 16 but others have not. 17 Potential mechanisms underlying this effect include statin action on sympathetic activity, on prenylation of proteins in vascular smooth muscle cells, and on endothelial potassium channels.…”

Section: Discussionmentioning

confidence: 50%

Timing and Dose of Statin Therapy Define Its Impact on Inflammatory and Endothelial Responses During Myocardial Infarction

Sposito

Santos

Faria

et al. 2011

ATVB

View full text Add to dashboard Cite

Objective-Clinical trials of statins during myocardial infarction (MI) have differed in their therapeutic regimes and generated conflicting results. This study evaluated the role of the timing and potency of statin therapy on its potential mechanisms of benefit during MI. Methods and Results-ST-elevation MI patients (nϭ125) were allocated into 5 groups: no statin; 20, 40, or 80 mg/day simvastatin starting at admission; or 80 mg/day simvastatin 48 hours after admission. After 7 days, all patients switched their treatment to 20 mg/day simvastatin for an additional 3 weeks and then underwent flow-mediated dilation in the brachial artery. As of the second day, C-reactive protein (CRP) differed between non-statin users (12.0Ϯ4

show abstract

Intensity of Lipid Lowering With Statins and Brachial Artery Vascular Endothelium Reactivity After Acute Coronary Syndromes (from the BRAVER Trial)

Cited by 34 publications

References 17 publications

Switching to Aggressive Statin Improves Vascular Endothelial Function in Patients with Stable Coronary Artery Disease

Switching to Aggressive Statin Improves Vascular Endothelial Function in Patients with Stable Coronary Artery Disease

Effects of Valsartan, an Angiotensin II Receptor Blocker, on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction Who Receive an Angiotensin-Converting Enzyme Inhibitor

Timing and Dose of Statin Therapy Define Its Impact on Inflammatory and Endothelial Responses During Myocardial Infarction

Contact Info

Product

Resources

About